Uramustine
(Redirected from Uracil mustard)
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Protein binding | 5% |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.574 |
Chemical and physical data | |
Formula | C8H11Cl2N3O2 |
Molar mass | 252.10 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Uramustine (INN) or uracil mustard is a chemotherapy drug which belongs to the class of alkylating agents.[1] It is used in lymphatic malignancies such as non-Hodgkin's lymphoma. It works by damaging DNA, primarily in cancer cells that preferentially take up the uracil due to their need to make nucleic acids during their rapid cycles of cell division. The DNA damage leads to apoptosis of the affected cells. Bone marrow suppression and nausea are the main side effects.
Chemically it is a derivative of nitrogen mustard and uracil.
References
- ^ Ghorani-Azam A, Balali-Mood M (2015). "Clinical pharmacology and toxicology of mustard compounds.". In Balali-Mood M, Abdollahi M (eds.). Basic and clinical toxicology of mustard compounds. Cham: Springer. p. 74. ISBN 978-3-319-23874-6.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles with changed DrugBank identifier
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- IARC Group 2B carcinogens
- Nitrogen mustards
- Pyrimidinediones
- Organochlorides
- Uracil derivatives
- Chloroethyl compounds
- All stub articles
- Antineoplastic and immunomodulating drug stubs